Back to Journals » Therapeutics and Clinical Risk Management » Volume 7
Current and emerging treatments for the management of myasthenia gravis
Authors Sathasivam S
Published 22 July 2011 Volume 2011:7 Pages 313—323
DOI https://doi.org/10.2147/TCRM.S14015
Review by Single anonymous peer review
Peer reviewer comments 2
Sivakumar Sathasivam
The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK
Abstract: Myasthenia gravis is an autoimmune neuromuscular disorder. There are several treatment options, including symptomatic treatment (acetylcholinesterase inhibitors), short-term immunosuppression (corticosteroids), long-term immunosuppression (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid acting short-term immunomodulation (intravenous immunoglobulin, plasma exchange), and long-term immunomodulation (thymectomy). This review explores in detail these different treatment options. Potential future treatments are also discussed.
Keywords: acetylcholinesterase inhibition, immunosuppression, immunomodulation, thymectomy
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.